Liver fibrosis is a condition characterized by excessive production and deposition of extracellular matrix proteins in the liver tissue. Accumulation of this matrix proteins leads to scarring and damage of the liver architecture. Conventional treatments for liver fibrosis include corticosteroids, immunosuppressive drugs, and liver transplantion. However, these treatment options have several limitations including high costs and risks of side effects. This has propelled research on more effective and advanced targeted therapies such as anti-fibrotic drugs. Anti-fibrotic drugs work by interfering with specific steps in fibrogenesis or stimulating resolution of fibrosis.

The global liver fibrosis treatment market is estimated to be valued at US$ 16.29 Bn in 2023 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
Growing adoption of advanced therapies: The key driver augmenting growth of the liver fibrosis treatment market is growing adoption of advanced targeted anti-fibrotic therapies. Anti-fibrotic drugs have shown promise in resolution of liver fibrosis with lesser side effects compared to conventional therapies. Drugs targeting IL-13/STAT-6, CTGF, TGF-β, LOXL2, and galectin-3 signaling pathways are currently under clinical trials and their expected availability is anticipated to boost the market growth over the forecast period. Growing diagnosis rates: Rising incidence of chronic liver diseases worldwide leading to liver fibrosis has increased diagnosis rate significantly. Increasing awareness regarding early diagnosis and management of liver fibrosis is also propelling the market growth.

Segment Analysis
The liver fibrosis treatment market is segmented into diagnostic tests and therapeutic segment. The therapeutic segment dominates the market owing to increasing adoption rate of drugs for treatment of liver fibrosis. The therapeutic segment comprises antiviral drugs, antifibrotic drugs and immuno-modulators. Antifibrotic drugs are the largest sub-segment as these drugs reduce fibrous tissue formation in liver and treat liver fibrosis effectively.

PEST Analysis
Political: Government initiatives to spread awareness regarding liver diseases is driving growth. However, stringent regulatory policies for drug approval can hamper market growth.
Economic: Rising healthcare expenditure and improvement in reimbursement scenario for fibrosis treatment is fueling market growth. However, high cost of treatment in developing nations poses challenges.
Social: Increasing alcohol consumption and growing obesity rates have increased risk of liver fibrosis, boosting demand. However, social stigma associated with liver diseases can hinder patients from timely diagnosis and treatment.
Technological: Advancements in diagnostic techniques like ELF test and FibroScan have improved accuracy of fibrosis detection. Development of novel and effective antifibrotic drugs is also supporting market expansion.

Key Takeaways
The global liver fibrosis treatment market is expected to witness high growth on account of rising prevalence of chronic liver diseases. The global liver fibrosis treatment market is estimated to be valued at US$ 16.29 Bn in 2023 and is expected to exhibit a CAGR of 4.9% over the forecast period 2023 to 2030.

Regionally, North America dominates the market and is expected to grow at a CAGR of 5.1% during forecast period due to strong healthcare infrastructure and availability of advanced treatment options in the region. Asia Pacific is poised to be the fastest growing region owing to large patient pool, rising awareness and improving healthcare scenario.

Key players operating in the liver fibrosis treatment market are Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, NESTLÉ S.A., DANONE S.A., B.Braun Melsungen AG, Mead Johnson & Company, LLC, Perrigo Company PLC, Koru Nutrition Inc., and Koninklijke DSM N.V. Among these, Abbott Laboratories holds the leading market position owing to its diverse product portfolio for liver fibrosis diagnosis and treatment.

Get more insights on this topic:

https://www.dailyprbulletin.com/liver-fibrosis-treatment-market-size-market-share-analysis/